Summary

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel discuss a couple of liver-directed trials in metastatic uveal melanoma. They focus on the CHOPIN and SCANDIUM trials, the combination of liver-directed therapies with systemic treatments, and the safety and efficacy of these approaches. The conversation highlights the innovative efforts of European investigators and the need for adaptive trial designs in rare diseases.

Keywords

melanoma, uveal melanoma, SCANDIUM, CHOPIN, liver directed therapy, systemic therapy, checkpoint inhibitors, cancer research, clinical trials, treatment options

Takeaways

We have limited treatment options for metastatic uveal melanoma.

Combining liver-directed therapy with systemic therapy is being explored.

Future trials are needed to understand optimal sequencing of therapies.

Adaptive trial designs may be challenging in rare cancers.

European investigators are leading innovative trials in this field.

The importance of collaboration in cancer research is emphasized.

Sound Bites

"We have a couple of approved agents."

"Is it safe to combine these therapies?"

"The IHP treatment had a superior response rate."

Chapters

00:00 Introduction and Icebreaker Question

01:52 Background and Objectives of the Studies

04:17 Results and Conclusions of the Scandium, Scandium-2, and Chopin Studies

06:28 Feasibility of Adaptive Trials for Rare Cancers

08:52 The Importance of International Collaboration in Uveal Melanoma Research

09:48 Closing Remarks and Future Directions